Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)
The summary for the Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01) Federal Grant is detailed below.
It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section.
If these sections are incomplete, please visit the website of the government agency that is offering this grant.
| Federal Grant Title: | EARLY CLINICAL TRIALS OF NEW ANTI-CANCER AGENTS WITH PHASE 1 EMPHASIS (U01) |
| Federal Agency Name: | National Institutes of Health |
| Program Name: | Cancer Treatment Research |
| Grant Categories: | Education Health |
| CFDA Number: | 93.395 |
| Funding Opportunity Number: | RFA-CA-07-031 |
| Posted Date: | Dec 12, 2006 |
| Creation Date: | Dec 12, 2006 |
| Original Application Deadline: | Mar 27, 2007 |
| Current Application Deadline: | Information not provided |
| Archive Date: | Apr 26, 2007 |
| Total Program Funding: | $8,260,000 |
| Maximum Federal Grant Award: | Information not provided |
| Minimum Federal Grant Award: | Information not provided |
| Expected Number of Awards: | 14 |
| Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Private institutions of higher education For profit organizations other than small businesses Small businesses
- Additional Information on Eligibility
- Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Only U.S. and Canadian institutions (*) are eligible to apply. Other Foreign institutions may participate in the program through collaborations with U.S. and/or Canadian applicant organizations.
- Grant Description
- The purpose of this Funding Opportunity Announcement (FOA) is to continue funding for early development clinical trials of investigational new anticancer drugs sponsored by the NCI Cancer Therapy Evaluation Program (CTEP). The NCI solicits applications from established centers with clinical and scientific experience and patient resources to perform Phase 1 single agent clinical trials, Phase 1 agent combination clinical trials, limited Phase 2 clinical trials, and pilot clinical trials of novel anticancer agents. In addition to the clinical evaluation of new agents, the objectives include the characterization of the effects of these agents on their targets. This objective is to be addressed through the integration of suitable biochemical, pathological, immunological, molecular, and/or imaging methods and correlating the effects of the agents with clinically relevant endpoints.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-031.html http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-07-031.html
- Grant Announcement Contact
- NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN) (UM1)
- • Planning for a National Center for Particle Beam Radiation Therapy Research (P20)
- • A Data Resource for Analyzing Blood and Marrow Transplants (Limited Competition U24)
- • Pediatric Phase 1/Pilot Consortium (Limited Competition UM1)
- • Childhood Cancer Survivor Study (CCSS)(Limited Competition U24)
- • Breast and Prostate Cancer Data Quality and Patterns of Care Study
- • Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults
- • National Cooperative Drug Discovery Groups for Cancer
- More Grants from the National Institutes of Health
- • NIAMS Clinical Trial Outcome Instrument Development Grant Program (U01)
- • Biophysical and Biomechanical Aspects of Embryonic Development (R01)
- • Biophysical and Biomechanical Aspects of Embryonic Development (R21)
- • Dual Purpose with Dual Benefit: Research in Biomedicine and Agriculture Using Agricultural...
- • MARC Undergraduate Student Training in Academic Research (U-STAR) National Research Servic...